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α/β which might also reflect more uniformity in response 
perhaps more characteristic of lower proliferative or early-
stage disease. This has resulted in new efforts to test 
hypofractionation which have also been enabled by better 
dose localization achievable with image-guided Volumetric 
Modulated Arc Therapy. 
There is evidence that the LQ model becomes less reliable at 
doses per fraction < 1 Gy, due to possible low-dose hyper-
radiosensitivity, and also at > 6 Gy per fraction for reasons 
not yet understood though increasing vascular damage and 
immunological/inflammatory effects occur at higher doses 
per fraction. It is axiomatic that LQ must indeed 
overestimate effect at very high doses per fraction because 
the effective D0 would become unrealistically low. This 
makes the outcome of hypofractionated regimes less 
predictable: using LQ at high doses per fraction would be 
playing safe in predicting toxicity of hypofractionation, while 
overestimating the effect on the target malignancy, noting 
that possible hypoxia in a tumor could also limit the 
effectiveness of large dose fractions. 
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Today’s external-beam radiotherapy (EBRT) is technologically 
sophisticated but radiobiologically primitive. Since the late 
1980s ‘Hi-tech’ has dominated EBRT at the expense of 
‘radiobiological intelligence’. Furthermore we have become 
slaves to the mantra  ‘evidence-based medicine’, with 
 evidence = phase-3 clinical trials: this ties our hands behind 
our backs. We prostrate ourselves before the ‘Collective 
Dose-Escalation Deity’ e.g. via advances such as MLCs, IMRT, 
even protons but largely reject individual dose-escalation 
based on (normal-tissue) patient DVHs   - this is illogical and 
does patients a disservice. We have become ‘hostages to 
commercial fortune’ – if the companies say ‘oh we cannot 
give you TCP or NTCP in our planning system in case someone 
sues us’ we meekly accept this!  This lamentable ‘worship of 
commercial interests’ is a negation of our dignity as scientists 
and our responsibility as medical practitioners. Today’s EBRT 
is ‘North Korean’ – instead it should be ‘South Korean’ i.e. 
based on enterprise and intelligence. Evolution equipped us 
with creative brains, which can do so much more than follow 
‘safety first’ protocols developed by committees. The ‘Hi-
tech’ gadgets of today are impressive but our use of them 
will remain largely pedestrian without the application of 
‘radiobiological intelligence’ – our patients expect no less.  
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The debate revolves around the impact of technology in 
radiotherapy (RT). RT as a field has a long tradition of high 
technology involvement, and practitioners are used to 
frequent technology advances. Recent technology advances 
include advanced imaging for planning and treatment 
verification, as well as rotational intensity modulation RT 
delivery. The ability to deliver the correct dose efficiently 
and with millimeter precision is now feasible at most modern 
RT departments. The question whether we have reached “the 
edge in radiotherapy” is therefore warranted. Even though 
the technology for planning and delivery has evolved, RT 
clinics rely much on manual procedures for tumor 
delineation, treatment planning, quality control test and 
treatment adaptation. Simultaneously, many RT clinics face 
the challenge of rising patient numbers to treat using the 
same equipment and with less staff. Further, most RT clinics 
lack systematic follow-up of treatment outcomes. I argue in 
this talk that new technology can improve RT cost-
effectiveness and patient outcomes. In addition, improved 
technology is warranted for safe personalized dose 
prescription and adapted radiation therapy. Technology 
advances can allow for automated procedures in the 
preparation of treatments, including delineation and planning 
Information technology solutions could automate the follow-
up procedures, including evaluation of quality of life, local 
control, patterns of relapse and survival.   
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There is increasing interest and application of Magnetic 
Resonance Imaging simulation (MRI-SIM) into the radiotherapy 
localization and planning process. However, the knowledge 
base within the context of Radiation Therapy practice is still 
in development.  Further, workforce development and the 
training plans for RTTs working in this developing area of 
practice has been not yet been standardized. This session 
targeted at RTTs, aims to provide an overview of the issues 
involved in developing a service where MRI scans are acquired 
in the treatment position, for RT planning (MRI SIM). The 
session will review the basic principles of MR imaging, the 
rationale for its use in radiotherapy and typical pulse 
sequences and scan protocols used for radiotherapy 
localization (MR-SIM). The session will also provide 
an overview of MR scanner modifications and accessories 
utilized for MR-SIM. The typical clinical workflow for MR-SIM 
including patient preparation, safety issues, scan 
optimization and CT-MR image registration using clinical 
examples will be presented. An overview of common staffing 
models and training plans for RTT’s working in MR-SIM will be 
reviewed 
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